Interesting Facts

• Lundbeck Gains Amid Speculation of Antidepressant Success - Bloomberg
  

  Lundbeck Gains Amid Speculation of Antidepressant SuccessBloombergH.

• Mylan 1Q profit rises on Lexapro and EpiPen sales - BusinessWeek
  

  Mylan 1Q profit rises on Lexapro and EpiPen salesBusinessWeekGeneric drugmaker Mylan Inc.

• Generic competition for Lexapro/Cipralex hits Lundbeck's first-quarter - The Pharma Letter
  

  Generic competition for Lexapro/Cipralex hits Lundbeck's first-quarterThe Pharma LetterEBIT fell 32% to 882 million kroner, also shy of analysts' expectations of 895 million kroner, as the company faced generic competition for its flagship antidepressant Cipralex/Lexapro (escitalopram), which is sold by Forest Labs in the USA.

• Lundbeck keeps year outlook after Q1 lags forecasts - Reuters
  

  Lundbeck keeps year outlook after Q1 lags forecastsReuters* Q1 EBIT 882 mln DKK vs average forecast 925 mln * Keeps 2012 profit, revenue guidance * Says revenue grew when discounting Lexapro revenue COPENHAGEN, May 2 (Reuters) - Danish drugmaker Lundbeck stood by its forecasts for 2012 on Wednesday despite a .

• Lundbeck Sees Lower Libido Risk With New Antidepressant - Bloomberg
  

  Lundbeck Sees Lower Libido Risk With New AntidepressantBloombergIt will help Lundbeck, the Nordic region's second-largest drugmaker, replace lost revenue from its best-selling Lexapro antidepressant, which went off- patent in the US in March.